Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 3/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.36 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3792671 | 0.82 | L3MBTL1 (0.38) | CDK2CCNA2CCNA1AURKACDK1 | |
| SCHEMBL13373521 | 0.79 | ROCK2 (0.48) | ROCK2ROCK1ALDH1A1TSHR | |
| SCHEMBL22133040 | 0.73 | CCNA2 (0.55) | CDK2CCNA2ALDH1A1HPGDNPC1 | |
| SCHEMBL13373531 | 0.73 | RAB9A (0.51) | ALDH1A1HPGDNPC1POLBRAB9A | |
| SCHEMBL20310148 | 0.72 | ROCK2 (0.44) | CDK2CCNA2CCNA1AURKACDK1 | |
| SCHEMBL15883609 | 0.72 | PIK3C3 (0.44) | CDK2CCNA2CCNA1AURKACDK1 | |
| SCHEMBL27656821 | 0.69 | CDK2 (0.46) | CDK2CCNA2CCNA1AURKACDK1 | |
| SCHEMBL21894632 | 0.68 | GAA (0.64) | ALDH1A1HPGDNPC1POLBMAPT | |
| SCHEMBL9123801 | 0.67 | TSHR (0.38) | CDK2CCNA2CCNA1ROCK2ROCK1 | |
| SCHEMBL15656391 | 0.67 | ROCK2 (0.42) | CDK2CCNA2CCNA1AURKACDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1846393-B1 | 4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID PIPERIDIN-4-YLAMIDE ACID ADDITION SALTS AS KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2020-02-19 | — | — | EP | disclosed |
| US-8293767-B2 | 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide acid addition salts as kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2012-10-23 | — | — | US | disclosed |
| US-8293767-B2 | 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide acid addition salts as kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2012-10-23 | — | — | US | disclosed |
| US-20110274616-A1 | 4-(2,6-DICHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID PIPERIDIN-4-YLAMIDE ACID ADDITION SALTS AS KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-11-10 | — | — | US | disclosed |
| US-20110274616-A1 | 4-(2,6-DICHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID PIPERIDIN-4-YLAMIDE ACID ADDITION SALTS AS KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-11-10 | — | — | US | disclosed |
| US-8013163-B2 | 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide acid addition salts as kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2011-09-06 | — | — | US | disclosed |
| US-8013163-B2 | 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide acid addition salts as kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2011-09-06 | — | — | US | disclosed |
| US-20090318500-A1 | 4-(2, 6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl)-amide for the Treatment of Cancer | ASTEX THERAPEUTICS LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-20090318500-A1 | 4-(2, 6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl)-amide for the Treatment of Cancer | ASTEX THERAPEUTICS LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-20090012124-A1 | 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide acid addition salts as kinase inhibitors | ASTEX THERAPEUTICS LIMITED (UK) | 2009-01-08 | — | — | US | disclosed |
| US-20090012124-A1 | 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide acid addition salts as kinase inhibitors | ASTEX THERAPEUTICS LIMITED (UK) | 2009-01-08 | — | — | US | disclosed |
| WO-2007129066-A1 | 4- (2,6-DICHLORO-BENZOYLAMINO) -1H-PYRAZOLE-3-CARBOXYLIC ACID (1-METHANESULPHONYL-PIPERIDIN-4-YL) -AMIDE FOR THE TREATMENT OF CANCER | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-15 | — | — | WO | disclosed |
| CN-101066950-A | 4-amino-5-methylpyrazole derivatives and process for producing the same | SANKYO AGRO CO LTD (JP) | 2007-11-07 | — | — | CN | disclosed |
| CN-101062918-A | 4-amino-5-methylpyrazole derivatives and process for producing the same | SANKYO AGRO CO LTD (JP) | 2007-10-31 | — | — | CN | disclosed |
| CN-101062917-A | 4-amino-5-methylpyrazole derivatives and process for producing the same | SANKYO AGRO CO LTD (JP) | 2007-10-31 | — | — | CN | disclosed |
| WO-2006077426-A2 | 4- (2, 6-DICHLOROBENZOYLAMINO) -lH-PYRAZOLE-3 -CARBOXYLIC ACID PIPERIDIN- 4 -YLAMID ACID ADDITION SALTS AS KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| CN-1732155-A | 4-amino-5-methylpyrazole derivatives and process for producing the same | SANKYO AGRO CO LTD (JP) | 2006-02-08 | — | — | CN | disclosed |
| EP-1580189-A1 | 4-AMINO-5-METHYLPYRAZOLE DERIVATIVES AND PROCESS FOR PRODUCTION THEREOF | Sankyo Agro Company, Limited (JP) | 2005-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110274616-A1 | 4-(2,6-DICHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID PIPERIDIN-4-YLAMIDE ACID ADDITION SALTS AS KINASE INHIBITORS | MAP4K2, MAPKAPK2, MAP4K1 | CDK2 40/4885CCNA2 1327/4885CCNA1 1430/4885 |
| US-20090012124-A1 | 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide acid addition salts as kinase inhibitors | MAP4K2, MAPKAPK2, MAP4K1 | CDK2 40/4885CCNA2 1327/4885CCNA1 1430/4885 |
| US-20090318500-A1 | 4-(2, 6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl)-amide for the Treatment of Cancer | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA5A, PDK4 | CDK2 50/4885CCNA2 148/4885CCNA1 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.